BMRN (BioMarin Pharmaceutical) COGS-to-Revenue : 0.20 (As of Mar. 2025)

View and export this data going back to 1999. Start your Free Trial

What is BioMarin Pharmaceutical COGS-to-Revenue?

BioMarin Pharmaceutical's Cost of Goods Sold for the three months ended in Mar. 2025 was $152 Mil. Its Revenue for the three months ended in Mar. 2025 was $745 Mil.

BioMarin Pharmaceutical's COGS to Revenue for the three months ended in Mar. 2025 was 0.20.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BioMarin Pharmaceutical's Gross Margin % for the three months ended in Mar. 2025 was 79.66%.

BioMarin Pharmaceutical COGS-to-Revenue Historical Data

The historical data trend for BioMarin Pharmaceutical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMarin Pharmaceutical COGS-to-Revenue Chart

BioMarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.25

0.24

0.22

0.20

BioMarin Pharmaceutical Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.19	0.18	0.25	0.18	0.20

BioMarin Pharmaceutical COGS-to-Revenue Calculation

BioMarin Pharmaceutical's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	580.235	/	2853.915
	=	0.20

BioMarin Pharmaceutical's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	151.558	/	745.145
	=	0.20

BioMarin Pharmaceutical (NAS:BMRN) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BioMarin Pharmaceutical's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	151.558 / 745.145
	=	79.66 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

BioMarin Pharmaceutical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioMarin Pharmaceutical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioMarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioMarin Pharmaceutical Inc (NAS:BMRN) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Executives

Erin Burkhart	officer: GVP, Chief Accounting Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Charles Greg Guyer	officer: EVP, Chief Technical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller	officer: EVP, Chief Financial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
George Eric Davis	officer: VP, General Counsel	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jean Jacques Bienaime	director, officer: Chief Executive Officer	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Robert Ajer	officer: EVP, Chief Commercial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs	officer: Chief Medical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
V Bryan Lawlis	director
Richard A Meier	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon	director	770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I	director	C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612